title: Management of joint bleeding in hemophilia.
abstract: Hemarthrosis, the hallmark of severe hemophilia, is the major cause of serious bleeding events, disability and reduced quality of life in patients with factor VIII or factor IX deficiency. Joint bleeding is one of the greatest challenges confronting individuals treating hemophilia, and its economic impact is enormous. This article reviews the current management of hemophilic joint bleeding and discusses the potential impact of novel therapies.
authors.affiliation: Department of Pediatrics, Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA. mindy_l_simpson@rush.edu
authors.forename: Mindy L
authors.initials: ML
authors.lastname: Simpson
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Valentino
mesh_terms: D003029:Coagulants / Q000627:therapeutic use*; D005164:Factor IX / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D005169:Factor VIII / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D006395:Hemarthrosis / Q000517:prevention & control* / Q000628:therapy; D006467:Hemophilia A / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D007592:Joint Diseases / Q000517:prevention & control; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D003029:Coagulants; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX